ArticleCancer cell2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 331 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
331citing papers in PubMed, 3 pooled it
36.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
331 citing papers in PubMed, 3 syntheses or guidelines pooled it, 492 citations in OpenAlex.
- Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of PD-1/PD-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary.Frontiers in immunology · 2025Pooled it
- Macrophages and the immune microenvironment in OPMDs: a systematic review of the literature.Frontiers in oral health · 2025Pooled it
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- CD8 PET imaging with [Journal for immunotherapy of cancer · 2026Trial
- Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma.Scientific reports · 2026Trial
- Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma.EMBO molecular medicine · 2026Article
- The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies.Genes & diseases · 2026Review
- Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer.Immuno-oncology technology · 2026Review
- scRNA-Seq in Gastric Cancer Reveals Macrophage-Derived C1q as a Diagnostic Marker.Cancer science · 2026Article
- Elucidating the Mechanisms of Trichloroethylene-Induced Kidney Cancer: Network Toxicology, Molecular Docking, and In Vitro Validation.Journal of biochemical and molecular toxicology · 2026Article
- Article
- UPR-CEBPB-MIF Signaling Links to Macrophage Polarization and an Immunosuppressive Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.Annals of surgical oncology · 2026Article
- Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancer.Translational oncology · 2026Article
- Article
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
- SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8Nature communications · 2026Article
- CXCL13-CXCR5 signaling in CD8Cancer immunology, immunotherapy : CII · 2026Article
- Immunometabolic Stress and Immune Suppression in Clear-Cell Renal Cell Carcinoma: Perspectives in Therapeutic Strategy.International journal of molecular sciences · 2026Review
- Nano-enabled spatially selective protein degradation modulates lactate metabolism to potentiate antitumor immunity in liver cancer.Nature nanotechnology · 2026Article
271 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
35 authors at 6 institutions in 3 countries.
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Kelly StreetDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Kelly P BurkeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA.
David L CookmeyerHarvard Medical School, Boston, MA 02215, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA.
Thomas DenizeHarvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Christina B PedersenSection for Bioinformatics, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark; Center for Genomic Medicine, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark.
Satyen H GohilDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Academic Hematology, University College London, London, UK.
Nicholas SchindlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lucas PomeranceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Laure HirschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yue HouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Juliet FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Teddy HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ang CuiBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard-MIT Division of Health Sciences and Technology, MIT, Cambridge, MA 02139, USA.
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
John SteinharterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Gabrielle BouchardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Maxine SunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Erica M PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Wenxin XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Kathleen M MahoneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Bradley A McGregorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Michelle S HirschHarvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Steven L ChangHarvard Medical School, Boston, MA 02215, USA; Division of Urologic Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
David F McDermottHarvard Medical School, Boston, MA 02215, USA; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Sachet A ShuklaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lars R OlsenSection for Bioinformatics, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark; Center for Genomic Medicine, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark.
Sabina SignorettiHarvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Arlene H SharpeHarvard Medical School, Boston, MA 02215, USA; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Harvard Medical School & Brigham and Women's Hospital, Boston, MA 02115, USA.
Rafael A IrizarryDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: cwu@partners.org.
Harvard University · USBroad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USCopenhagen University Hospital · DK
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MEDAC: ENCODE Data Analysis CenterU24HG009446 · NHGRI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GERSTEIN, MARK BENDER, WENG, ZHIPING · 2017 to 2022
$10.4MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MPreprocessing and Analysis Tools for High-Throughput TechnologiesR01GM083084 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI IRIZARRY, RAFAEL ANGEL · 2007 to 2018
$4.4MData Analysis Tools for Emerging High-Throughput TechnologiesR35GM131802 · NIGMS · DANA-FARBER CANCER INST · PI Rafael Angel Irizarry · 2019 to 2026
$4.1MSingle cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4MImmunogenomic analytical approaches for research and clinical applicationsR50CA211482 · NCI · DANA-FARBER CANCER INST · PI SHUKLA, SACHET ASHOK · 2016 to 2020
$1.3MPhysical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccinesR21CA216772 · NCI · DANA-FARBER CANCER INST · PI KESKIN, DERIN B · 2018 to 2019
$420kNCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA155010NCI NIH HHS R21 CA216772NCI NIH HHS R50 CA211482NCI NIH HHS R50 CA251956NCI NIH HHS T32 CA009172NCI NIH HHS U24 CA224331NHGRI NIH HHS U24 HG009446NIGMS NIH HHS R01 GM083084NIGMS NIH HHS R35 GM131802
Abstract
The tumor immune microenvironment plays a critical role in cancer progression and response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the composition and phenotypic states of immune cells in this tumor are incompletely characterized. We performed single-cell RNA and T cell receptor sequencing on 164,722 individual cells from tumor and adjacent non-tumor tissue in patients with ccRCC across disease stages: early, locally advanced, and advanced/metastatic. Terminally exhausted CD8
Indexed as
Biomarkers, TumorCarcinoma, Renal CellCD8-Positive T-LymphocytesGene Expression Regulation, NeoplasticHumansImmunotherapyKidney NeoplasmsLymphocytes, Tumor-InfiltratingMacrophagesTumor MicroenvironmentBiomarkers, Tumorcancer immunotherapyCD8 T cell exhaustioncell-cell interactionclear cell renal cell carcinomaimmune cell atlassingle-cell RNA sequencingtumor-associated macrophages
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.